Recently, Bloomage Biotech (688363. SH) released its 2024 annual report performance forecast, which undoubtedly dropped a bombshell on the market. The net profit attributable to owners of the parent company is expected to be in the range of 146 million yuan to 175 million yuan, a year-on-year decrease of 70.47% to 75.36%; Net profit attributable to owners of the parent company after deducting non-recurring gains and losses is expected to be 80 million yuan to 109 million yuan, a year-on-year decrease of 77.78% to 83.69%. Such performance data instantly aroused many doubts in the market. Some people questioned its development prospects, believing that the decline in performance was a sign that the company was in decline; There have also been doubts about the company's management, especially the increase in overheads, which is seen as a sign of the company's operational inefficiencies.

However, when discussing the development potential of a company, it is obviously too one-sided to judge based solely on short-term performance growth data. The development of a business is a complex and dynamic process, and sustainability is the key criterion for measuring its potential. Just like a long-distance race, you can't just judge who wins by the speed at the start, but also the strategic adjustment, endurance reserve, and explosiveness in the sprint. Bloomage Biotech seems to be declining in performance at present, but this may be its "squatting" action in the process of strategic adjustment, in order to achieve a more powerful jump in the future.

Bloomage Biotech's unique four-wheel drive business model makes it unique in the market, and there is no company on the market that can match its business model. It covers four major business segments: raw materials, medical terminals, functional skin care products and functional foods, as a biotechnology and biomaterials industry chain platform company, if only a single business sector company is used to measure Bloomage Biotech, it is obviously inaccurate and incomplete. This layout of the whole industry chain has endowed Bloomage Biotech with stronger anti-risk ability and development resilience, from the R&D and production of raw materials to the sales of terminal products, forming an organic whole, and various business segments synergize with each other to jointly promote the development of the company.

In 2024, Bloomage Biotech underwent a strategic upgrade, which became an important milestone in its development history. Starting from the basic research of biology, this strategic upgrade focuses on the two basic disciplines of glycobiology and cell biology, and relies on the advantages of industrial transformation in the field of synthetic biology to provide scientific solutions for life and health. Starting from the upstream research and development of biomaterials, it runs through to brand building, and explores a path for the full-link transformation of biomaterials. This strategic upgrade is not accidental, but an inevitable choice of Bloomage Biotech after comprehensively considering its own development and industry trends.

From the perspective of the enterprise itself, it is an internal need to enhance the core competitiveness. Bloomage Biotech not only focuses on the current market competition, but also sets its sights on the global market, and is committed to providing global consumers with better and more efficient life and health products and services, and promoting the innovation and development of biotechnology and health industry. At the same time, the natural selection of the company's stage development has also prompted strategic upgrading. After years of development, Bloomage Biotech has three core competencies of R&D innovation, achievement transformation and market transformation, and its software and hardware strength have reached a relatively mature stage, providing a solid foundation for strategic upgrading.